Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 2Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Intellectual Disability 1Heart Failure 1Gynecologic Cancer 1Carcinoma, Non-Small-Cell Lung 1Blood Loss, Surgical 1Arrhythmias, Cardiac 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Population Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡